Cargando…
Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations
As part of the Vaccine Innovation Prioritisation Strategy (VIPS), three immunization-stakeholder consultations were conducted between September 2018 and February 2020 to ensure that countries’ needs drove the prioritization of vaccine product innovations. All consultations targeted respondents with...
Autores principales: | Mvundura, Mercy, Frivold, Collrane, Janik Osborne, Anna, Soni, Priyanka, Robertson, Joanie, Kumar, Sandeep, Anena, Jacqueline, Gueye, Abdoulaye, Menozzi-Arnaud, Marion, Giersing, Birgitte, Kahn, Anna-Lea, Scarna, Tiziana, Kristensen, Debra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657797/ https://www.ncbi.nlm.nih.gov/pubmed/34412922 http://dx.doi.org/10.1016/j.vaccine.2021.08.024 |
Ejemplares similares
-
A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy
por: Kristensen, Debra, et al.
Publicado: (2021) -
Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine
por: Mvundura, Mercy, et al.
Publicado: (2019) -
Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries
por: Giersing, Birgitte, et al.
Publicado: (2021) -
Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study
por: Seaman, Christopher P., et al.
Publicado: (2022) -
Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges
por: Hasso-Agopsowicz, Mateusz, et al.
Publicado: (2022)